CEO Biotech
An established figure in the realm of biotechnology focused on oncology, Patrick Mahaffy has a track record in pioneering drug development and commercialization across the US and Europe. Initially leading several Boulder, Colorado-based firms, he now resides in South Florida.
In his latest professional chapter, he held the CEO role at Clovis Oncology, a venture he co-founded in 2009. Under his guidance, the company made significant strides in developing treatments for ovarian and prostate cancer in the US and Europe, along with embarking on the early stages of clinical trials for innovative targeted radionuclide therapy. The company, however, had to close down in late 2022 due to the impacts of the COVID-19 pandemic on cancer diagnosis and regulatory challenges regarding a class of ovarian cancer drugs.
Before Clovis, he was at the helm of Pharmion from 2000 until its 2008 acquisition by Celgene (now merged into Bristol Myers Squibb). He led Nexstar Pharmaceuticals from 1992 until it joined forces with Gilead Sciences in 1998. His tenure at these firms was marked by the successful launch and commercialization of groundbreaking oncology drugs in the US and European markets.
Remarkably, the treatments developed under his leadership at these companies are still the primary standard of care or a significant part of the standard treatment regimen in their designated fields.
While he keeps a low profile regarding his charitable endeavors, he is a committed supporter of various philanthropic causes, focusing primarily on family assistance funds. He also holds a long-term position on the Board of Trustees at Lewis & Clark College.